Pfizer Protonix Settlement May Deter Price Bundling
This article was originally published in The Pink Sheet Daily
Executive Summary
$784.6m fine will resolve claims that Wyeth subsidiary paid hospitals steep discounts if they purchased both oral and IV Protonix while reporting higher prices to the government.
You may also be interested in...
Gilead Asks Supreme Court To Restrict False Claims Act Cases
Complaints should not be allowed to go forward if government knew of regulatory infraction but continued to pay for drug, Gilead argues, asking US high court to 'finish task' of its Escobar ruling.
Dr. Reddy's Defeat Of FCA Case Offers 'Guidepost' For Litigation After Escobar
Dismissal of False Claims Act suit against Dr. Reddy's shows impact of US Supreme Court's Escobar decision. Government FCA pharma recoveries shot up 58% from 2015 to 2016; graphic breaks out settlements by kickback, off-label promotion and improper billing cases.
Pharma Deals With The DOJ
A look at the settlement agreements pharma companies have struck with the Department of Justice in the last three years; the size of the deals has declined dramatically since 2012.